Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors

Scandinavian Journal of Rheumatology

Volumn 38, Issue 5, 2009, Pages 328-331

  Exarchou, S A ^a   Voulgari, P V ^a   Markatseli, T E ^a   Zioga, A ^a   Drosos, A A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALOPECIA AREATA; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GRANULOMA ANNULARE; HUMAN; LICHEN PLANUS; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN DEFECT; SKIN VASCULITIS; SPONDYLOARTHROPATHY; VASCULITIS; VITILIGO;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350049105     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740902922612     Document Type: Article

References (16)

1. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;/163:/1521-8.
2. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;/126:/13-30.
3. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;/52:/ 2513-8.
4. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;/67:/567-70.
5. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003;/206:/388-90.
6. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;/7:/ R666-76.
7. Perez-Zafrilla B, Garcia de Yebenes M, Dauden E, Gomez- Reino JJ, Carmona L. Is psoriasis a complication of anti-TNF treatment? Arthritis Rheum 2008;/58(Suppl):/S781.
8. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 2005;/125:/xiv-xv.
9. Alexander JS, Paniker PU. A ring-shaped eruption. Am J Med 2006;/119:/125-7.
10. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003;/15:/380-6.
11. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapyinduced vasculitis: case series. J Rheumatol 2003;/30:/2287-91.
12. De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin Exp Rheumatol 2003;/21:/726-32.
13. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;/41:/1303-7.
14. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002;/206:/496-501.
15. Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009;/129:/ 315-9.
16. Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman SR. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol 2008;/7:/164-8.